{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:57:02Z","timestamp":1780657022927,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"23-24","license":[{"start":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T00:00:00Z","timestamp":1447372800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s10354-015-0399-9","type":"journal-article","created":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T07:40:03Z","timestamp":1447400403000},"page":"499-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Subantimicrobial-dose doxycycline monohydrate in dermatology","Doxyzyklinmonohydrat in subantimikrobieller Dosierung in der Dermatologie"],"prefix":"10.1007","volume":"165","author":[{"given":"Uwe","family":"Wollina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,13]]},"reference":[{"key":"399_CR1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.phrs.2010.10.004","volume":"63","author":"MO Griffin","year":"2011","unstructured":"Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res. 2011;63:102\u20137.","journal-title":"Pharmacol Res"},{"key":"399_CR2","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1517\/14740338.7.5.571","volume":"7","author":"B Sloan","year":"2008","unstructured":"Sloan B, Scheinfeld N. The use and safety of doxycycline hyclate and other second-generation tetracyclines. Expert Opin Drug Saf. 2008;7:571\u20137.","journal-title":"Expert Opin Drug Saf"},{"key":"399_CR3","doi-asserted-by":"crossref","first-page":"329418","DOI":"10.1155\/2015\/329418","volume":"2015","author":"R Di Caprio","year":"2015","unstructured":"Di Caprio R, Lembo S, Di Constanzo L, Balato A, Monfrecola G. Anti-inflammatory properties of low and high doxycycline doses: an in vitro study. Mediators Inflamm. 2015;2015:329418.","journal-title":"Mediators Inflamm"},{"key":"399_CR4","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1902\/jop.2000.71.9.1472","volume":"71","author":"J Thomas","year":"2000","unstructured":"Thomas J, Walker C, Bradshaw M. Long-term use of subantimicrobial dose doxycycline does not lead to changes in antimicrobial susceptibility. J Perdontol. 2000;71:1472\u201383.","journal-title":"J Perdontol"},{"key":"399_CR5","first-page":"118","volume":"74","author":"JQ Del Rosso","year":"2004","unstructured":"Del Rosso JQ. A status report on the use of subantimicrobial-dose doxycycline: a review of the biologic and antimicrobial effect of the tetracyclines. Cutis. 2004;74:118\u201322.","journal-title":"Cutis"},{"key":"399_CR6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1358\/dot.2007.43.1.1025697","volume":"43","author":"B Berman","year":"2007","unstructured":"Berman B, Perez OA, Zell D. Update on rosacea and anti-inflammatory-dose doxycycline. Drugs Today (Barc). 2007;43:27\u201334.","journal-title":"Drugs Today (Barc)"},{"key":"399_CR7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/jid.2012.14","volume":"132","author":"KN Kanada","year":"2012","unstructured":"Kanada KN, Nakatsuji T, Gallo RL. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol. 2012;132:1435\u201342.","journal-title":"J Invest Dermatol"},{"key":"399_CR8","doi-asserted-by":"crossref","first-page":"50","DOI":"10.12703\/P6-50","volume":"6","author":"U Wollina","year":"2014","unstructured":"Wollina U. Recent advances in the understanding and management of rosacea. F1000Prime Rep. 2014;6:50.","journal-title":"F1000Prime Rep"},{"key":"399_CR9","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","volume":"56","author":"JQ Del Rosso","year":"2007","unstructured":"Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56:791\u2013802.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"399_CR10","first-page":"16","volume":"86","author":"JQ Del Rosso","year":"2010","unstructured":"Del Rosso JQ. Effectiveness and safety of doxycycline 40\u00a0mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial. Cutis. 2010;86(5\u00a0Suppl.):16\u201325.","journal-title":"Cutis"},{"key":"399_CR11","first-page":"703","volume":"11","author":"JQ Del Rosso","year":"2012","unstructured":"Del Rosso JQ, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender. J Drugs Dermatol. 2012;11:703\u20137.","journal-title":"J Drugs Dermatol"},{"key":"399_CR12","first-page":"1376","volume":"10","author":"SM Johnson","year":"2011","unstructured":"Johnson SM, LeVine P. Self-reported treatment impressions and satisfaction of papulopustular rosacea patients treated with doxycycline, USP, 40\u00a0mg capsules. J Drugs Dermatol. 2011;10:1376\u201381.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"399_CR13","first-page":"7","volume":"86","author":"GF Webster","year":"2010","unstructured":"Webster GF. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40\u00a0mg (30-mg immediate-release and 10-mg delayed-release beads). Cutis. 2010;86(5\u00a0Suppl.):7\u201315.","journal-title":"Cutis"},{"key":"399_CR14","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1473-2165.2009.00456.x","volume":"8","author":"U Wollina","year":"2009","unstructured":"Wollina U, Verma SB. Rosacea and rhinophyma: not curse of the Celts but Indo Eurasians. J Cosmet Dermatol. 2009;8:234\u20135.","journal-title":"J Cosmet Dermatol"},{"key":"399_CR15","first-page":"1219","volume":"11","author":"AF Alexis","year":"2012","unstructured":"Alexis AF, Webster G, Preston NJ, Caveney SW, Gottschalk RW. Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with rosacea: an analysis by Fitzpatrick skin type. J Drugs Dermatol. 2012;11:1219\u201322.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"399_CR16","first-page":"26","volume":"86","author":"HE Baldwin","year":"2010","unstructured":"Baldwin HE. A community-based study of the effectiveness of doxycycline 40\u00a0mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea. Cutis. 2010;86(5\u00a0Suppl.):26\u201336.","journal-title":"Cutis"},{"key":"399_CR17","first-page":"641","volume":"6","author":"JF Fowler Jr","year":"2007","unstructured":"Fowler JF Jr. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1\u2009% in the treatment of rosacea. J Drugs Dermatol. 2007;6:641\u20135.","journal-title":"J Drugs Dermatol"},{"key":"399_CR18","first-page":"607","volume":"9","author":"JQ Del Rosso","year":"2010","unstructured":"Del Rosso JQ, Bruce S, Jarratt M, Menter A, Staedtler G. Efficacy of topical azelaic acid (AzA) gel 15\u2009% plus oral doxycycline 40\u00a0mg versus metronidazole gel 1\u2009% plus oral doxycycline 40\u00a0mg in mild-to-moderate papulopustular rosacea. J Drugs Dermatol. 2010;9:607\u201313.","journal-title":"J Drugs Dermatol"},{"key":"399_CR19","first-page":"488","volume":"81","author":"AB Fender","year":"2008","unstructured":"Fender AB, Ignatovich Y, Mercurio MG. Pyoderma faciale. Cutis. 2008;81:488\u201390.","journal-title":"Cutis"},{"key":"399_CR20","first-page":"763","volume":"13","author":"LA Smith","year":"2014","unstructured":"Smith LA, Meehan SA, Cohen DE. Rosacea fulminans with extrafacial lesions in an elderly man: successful treatment with subantimicrobial-dose doxycycline. J Drugs Dermatol. 2014;13:763\u20135.","journal-title":"J Drugs Dermatol"},{"key":"399_CR21","first-page":"904","volume":"9","author":"I Pfeffer","year":"2011","unstructured":"Pfeffer I, Borelli C, Zierhut M, Schaller M. Treatment of ocular rosacea with 40\u00a0mg doxycycline in a slow release form. J Dtsch Dermatol Ges. 2011;9:904\u20137.","journal-title":"J Dtsch Dermatol Ges"},{"key":"399_CR22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/ICO.0000000000000051","volume":"33","author":"B Sobolewska","year":"2014","unstructured":"Sobolewska B, Doycheva D, Deuter C, Pfeffer I, Schaller M, Zierhut M. Treatment of ocular rosacea with once-daily low-dose doxycycline. Cornea. 2014;33:257\u201360.","journal-title":"Cornea"},{"key":"399_CR23","first-page":"2141","volume":"149","author":"K Thestrup-Pedersen","year":"1987","unstructured":"Thestrup-Pedersen K, Hjorth N. Red scalp: a previously undescribed disease of the scalp? Ugeskr Laeger. 1987;149:2141\u20132.","journal-title":"Ugeskr Laeger"},{"key":"399_CR24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1159\/000228319","volume":"219","author":"PA Oberholzer","year":"2009","unstructured":"Oberholzer PA, Nobbe S, Kolm I, Kerl K, Kamarachev J, Tr\u00fceb RM. Red scalp disease\u2014a rosacea-like dermatosis of the scalp? Successful therapy with oral tetracycline. Dermatology. 2009;219:179\u201381.","journal-title":"Dermatology"},{"key":"399_CR25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72:203\u201318.","journal-title":"J Am Acad Dermatol"},{"key":"399_CR26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72:221\u201336.","journal-title":"J Am Acad Dermatol"},{"key":"399_CR27","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.jaad.2014.09.002","volume":"71","author":"M Sanlorenzo","year":"2014","unstructured":"Sanlorenzo M, Choudhry A, Vujic I, et al. Comparative profile of cutaneous adverse events: BRAF\/MEK inhibitor combination therapy versus BRAF monotherapy in melanoma. J Am Acad Dermatol. 2014;71:1102\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"399_CR28","doi-asserted-by":"crossref","unstructured":"Sibaud V, Tournier E, Roch\u00e9 H, Del Giudice P, Delord JP, Hubiche T. Late epidermal growth factor receptor inhibitor-related papulopustular rash: a distinct clinical entity. Clin Exp Dermatol. 2015. doi: 10.1111\/ced.12675 .","DOI":"10.1111\/ced.12675"},{"key":"399_CR29","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/jid.2008.237","volume":"129","author":"M Shibata","year":"2009","unstructured":"Shibata M, Katsuyama M, Onodera T, Ehama R, Hosoi J, Tagami H. Glucocorticoids enhance Toll-like receptor 2 expression in human keratinocytes stimulated with Propionibacterium acnes or proinflammatory cytokines. J Invest Dermatol. 2009;129:375\u201382.","journal-title":"J Invest Dermatol"},{"key":"399_CR30","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/jdv.12365","volume":"28","author":"J Vaubel","year":"2014","unstructured":"Vaubel J, Livingstone E, Schadendorf D, Zimmer L. Retarded low-dose doxycycline for EGFR or MEK inhibitor-induced papulopustular rash. J Eur Acad Dermatol Venereol. 2014;28:1685\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"399_CR31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4103\/0378-6323.74974","volume":"77","author":"SK Rathi","year":"2011","unstructured":"Rathi SK, Kumrah L. Topical corticosteroid-induced rosacea-like dermatitis: a clinical study of 110 cases. Indian J Dermatol Venereol Leprol. 2011;77:42\u20136.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"399_CR32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-014-0067-7","volume":"15","author":"T Tempark","year":"2014","unstructured":"Tempark T, Shwayder TA. Perioral dermatitis: a review of the condition with special attention to treatment options. Am J Clin Dermatol. 2014;15:101\u201313.","journal-title":"Am J Clin Dermatol"},{"key":"399_CR33","first-page":"20","volume":"4","author":"JQ Rosso","year":"2011","unstructured":"Rosso JQ. Management of papulopustular rosacea and perioral dermatitis with emphasis on iatrogenic causation or exacerbation of inflammatory facial dermatoses: use of doxycycline-modified release 40\u00a0mg capsule once daily in combination with properly selected skin care as an effective therapeutic approach. J Clin Aesthet Dermatol. 2011;4:20\u201330.","journal-title":"J Clin Aesthet Dermatol"},{"key":"399_CR34","first-page":"CD003262","volume":"4","author":"EJ Zuuren van","year":"2015","unstructured":"van Zuuren EJ, Fedorowicz Z, Carter B, van der Linden MM, Charland L. Interventions for rosacea. Cochrane Database Syst Rev. 2015;4:CD003262.","journal-title":"Cochrane Database Syst Rev"},{"key":"399_CR35","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3341\/kjo.2005.19.4.258","volume":"19","author":"SE Yoo","year":"2005","unstructured":"Yoo SE, Lee DC, Chang MH. The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol. 2005;19:258\u201363.","journal-title":"Korean J Ophthalmol"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-015-0399-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-015-0399-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-015-0399-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T16:11:11Z","timestamp":1559146271000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-015-0399-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,13]]},"references-count":35,"journal-issue":{"issue":"23-24","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["399"],"URL":"https:\/\/doi.org\/10.1007\/s10354-015-0399-9","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,13]]}}}